Makampani a Pharmaceutical ndi R&D Investment ya Biopharmaceuticals

      Kukula kwamakampani opanga mankhwala padziko lonse lapansi mu 2023 kudakali m'nthawi yodabwitsa, pomwe makampani azamankhwala apanyumba ndi akunja azisamaliranso kwambiri ndalama za R&D.M'zaka khumi zikubwerazi, makampani opanga mankhwala akhoza kukumanabe ndi kusintha kwakukulu, kusintha kwakukulu ndi chikhalidwe cha ndondomeko zapadziko lonse.M'malo osinthika kwambiri, makampani opanga mankhwala amakhalanso ndi njira zosiyanasiyana zothanirana nazo, monga kubwereza kwa mankhwala, nthambi yamalonda, zatsopano zachitsanzo ndi zina zotero.

         Makampani opanga mankhwala nawonso akukumana ndi zovuta zazikulu.Tsopano, makampani opanga mankhwala amasamalira kwambiri ndalama za R&D ndikuwonjezera bajeti. R&D Investment.Ndipo BeiGene's TIGIT inhibitor idayika $2.9 biliyoni, Vidicumumab ya Rongchang Bio imayika $2.6 biliyoni.Nthawi yomweyo, m'zaka zaposachedwa, ndikusintha kwa matenda a anthu, mankhwala achilengedwe akufunikanso, ndipo makampani ambiri akuyika njira ya R&D biological dru.g. 

       Hunan Honya Biotec Co., Ltd. wadzipereka kupanga zida zapamwamba za DNA kaphatikizidwe ndi mayankho ophatikizika ophatikizika kwazaka zopitilira 10.Kafukufuku wodziyimira pawokha komanso kapangidwe kachitukuko, gulu lomwe lili ndi msana wa maprofesa ndi mainjiniya a biology oposa 20 omwe adamaliza maphunziro awo ku yunivesite ya Tsinghua.Titha kupereka zapamwamba zopangira zinthu zopangira kafukufuku wa sayansi ya moyo monga kafukufuku wa majini, matenda a maselo, chitukuko cha mankhwala a nucleic acid, etc. Pa nthawi yomweyi, ndife ogwirizana kwambiri ndi makampani ambiri opanga mankhwala, kuwathandiza kuti apititse patsogolo R & D ndi kusintha. kuchita bwino.Gwirani ntchito limodzi kuti muthandizire chitukuko ndi kupita patsogolo kwamakampani azachipatala mpaka zaka zana zatsopano.

.